Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Some patients dropped out of the trial early because they had lost so much weight.

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...